Lee Ainslie's CDTX Position Overview
Lee Ainslie (via Maverick Capital LTD) currently holds 455,978 shares of Cidara Therapeutics, Inc. (CDTX) worth $100.72 M, representing 1.08% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Lee Ainslie has initiated a new position in CDTX, representing a fresh investment thesis on this company. Largest addition occurred in Q4 2025, adding 38,428 shares.
Analysis based on 13F filings available since 2013 Q2
Lee Ainslie's Cidara Therapeutics (CDTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cidara Therapeutics (CDTX) Trades by Lee Ainslie
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2025 | +417,550 | New Buy | 417,550 | $95.76 |
| Q4 2025 | +38,428 | Add 9.20% | 455,978 | $220.89 |
Lee Ainslie's Cidara Therapeutics Investment FAQs
Lee Ainslie first purchased Cidara Therapeutics, Inc. (CDTX) in Q3 2025, acquiring 417,550 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie has held Cidara Therapeutics, Inc. (CDTX) for 2 quarters since Q3 2025.
Lee Ainslie's largest addition to Cidara Therapeutics, Inc. (CDTX) was in Q3 2025, adding 417,550 shares worth $39.98 M.
According to the latest 13F filing for Q4 2025, Lee Ainslie's firm, Maverick Capital LTD, owns 455,978 shares of Cidara Therapeutics, Inc. (CDTX), valued at approximately $100.72 M.
As of the Q4 2025 filing, Cidara Therapeutics, Inc. (CDTX) represents approximately 1.08% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.
Lee Ainslie's peak holding in Cidara Therapeutics, Inc. (CDTX) was 455,978 shares, as reported at the end of Q4 2025.